Why do african americans face more kidney problems? this study looks at exercise
NCT ID NCT03981640
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study compares kidney blood flow during exercise in healthy young African American and White adults. Researchers want to see if African Americans have a larger drop in kidney blood flow during physical activity, which could help explain higher rates of heart and kidney disease in this group. Participants will do cycling, cold water hand tests, and mental math during two lab visits.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- What this could lead to
- If successful, this study could help explain why African American adults face higher rates of heart and kidney problems, guiding future prevention strategies.
- What could go wrong
- This is a small, early-stage observational study in healthy people, so findings may not apply to those with existing health conditions or lead directly to treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Massachusetts Boston
RECRUITINGBoston, Massachusetts, 02125, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test